365 related articles for article (PubMed ID: 28067828)
1. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E; Del Re M; Fidilio L; Fogli S; Danesi R; Di Paolo A
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067828
[TBL] [Abstract][Full Text] [Related]
2. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
3. Transporter pharmacogenetics and statin toxicity.
Niemi M
Clin Pharmacol Ther; 2010 Jan; 87(1):130-3. PubMed ID: 19890253
[TBL] [Abstract][Full Text] [Related]
4. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
[TBL] [Abstract][Full Text] [Related]
5. Clinical application of cardiovascular pharmacogenetics.
Voora D; Ginsburg GS
J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of pharmacogenetic variation on the effects of statins.
Maggo SD; Kennedy MA; Clark DW
Drug Saf; 2011 Jan; 34(1):1-19. PubMed ID: 21142270
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics and adverse drug reactions: the case of statins.
Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of statins treatment: Efficacy and safety.
Guan ZW; Wu KR; Li R; Yin Y; Li XL; Zhang SF; Li Y
J Clin Pharm Ther; 2019 Dec; 44(6):858-867. PubMed ID: 31436349
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics and tailored polypharmacy: an 80-year-old lady with rosuvastatin-associated rhabdomyolysis and maprotiline-related Ogilvie's syndrome
.
Sreter KB; Barisic B; Popovic-Grle S
Int J Clin Pharmacol Ther; 2017 May; 55(5):442-448. PubMed ID: 28257284
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
Lamoureux F; Duflot T;
Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.
Dou Y; Zhu X; Wang Q; Tian X; Cheng J; Zhang E
Ann Lab Med; 2015 May; 35(3):329-35. PubMed ID: 25932441
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate.
Pasanen MK; Miettinen TA; Gylling H; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2008 Oct; 18(10):921-6. PubMed ID: 18794729
[TBL] [Abstract][Full Text] [Related]
13. Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
Norata GD; Tibolla G; Catapano AL
Pharmacol Res; 2014 Oct; 88():107-13. PubMed ID: 24835295
[TBL] [Abstract][Full Text] [Related]
14. An update on efflux and uptake transporters as determinants of statin response.
Rocha KCE; Pereira BMV; Rodrigues AC
Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):613-624. PubMed ID: 29842801
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM; Goey AK; Ley AM; Strope JD; Figg WD
Methods Mol Biol; 2014; 1175():91-120. PubMed ID: 25150868
[TBL] [Abstract][Full Text] [Related]
16. Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example.
Sadee W
J Pharm Sci; 2013 Sep; 102(9):2924-9. PubMed ID: 23436703
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics and drug toxicity.
Nakamura Y
N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
[No Abstract] [Full Text] [Related]
18. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy.
Couvert P; Chapman MJ; Carrié A
Pharmacogenomics; 2011 Feb; 12(2):137-9. PubMed ID: 21332305
[No Abstract] [Full Text] [Related]
19. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.
Peters BJ; Rodin AS; Klungel OH; van Duijn CM; Stricker BH; van't Slot R; de Boer A; Maitland-van der Zee AH
Pharmacogenomics; 2010 Aug; 11(8):1065-76. PubMed ID: 20712525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
